New Tailored Tissue Adhesives by MIT Scientist By: Anne Trafton | MIT News Office After undergoing surgery to remove diseased sections of the colon, up to 30 percent of patients experience leakage from their sutures, which can cause life-threatening complications. Many efforts are under way to create new tissue glues [..]
U.S. FDA Approved ERLEADA™ for Prostate Cancer By: Janssen News The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved ERLEADA™ (apalutamide), a next-generation androgen receptor inhibitor,[1] for the treatment of patients with non-metastatic castration-resistant prostate cancer (NM-CRPC). ERLEADA™ is the first FDA-approved [..]
Common Traits of all Successful Entrepreneurs Every successful entrepreneur believes in Pareto’s Law more than the law of gravity. Pareto’s Law states that that 80 percent results come from 20 percent causes. Through experience, such entrepreneurs have learned that 20 percent of their actions yield 80 percent results. So they maximize their [..]
FDA Aproved First Diagnostic Blood Test for Traumatic Brain Injury By: Business Wire Banyan Biomarkers, Inc., a pioneer in developing biomarkers for traumatic brain injury (TBI), announced that the U.S. Food and Drug Administration (FDA) has granted the De Novo request for the commercialization of Banyan BTITM (Brain Trauma Indicator), an [..]
Tracking Patients’ Progress With Radio Signals and Machine Learning By: Elizabeth Dougherty In 2016, Jason Laramie attended a talk at the Massachusetts Institute of Technology (MIT) about a device that can see through walls. It can detect people, track their movement and breathing, and even see their hearts beating. Laramie, an [..]
Sandoz Announces US FDA Approval and Launch of Glatopa® for Relapsing Forms of Multiple Sclerosis By: Novartis News Sandoz, a Novartis division, today announced the US FDA approval and launch of Glatopa® (glatiramer acetate injection) 40 mg/mL. Glatopa (glatiramer acetate injection) 40 mg/mL is FDA-approved as a fully-substitutable, AP-rated generic version of Copaxone®* (glatiramer [..]
Novartis Receives FDA Approval for Cosentyx® Label Update to Include Moderate-to-Severe Scalp Psoriasis By: Novartis News Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Cosentyx® (secukinumab), the first interleukin-17A (IL-17A) inhibitor approved to treat moderate-to-severe plaque psoriasis[1]. The updated label includes Cosentyx data in moderate-to-severe [..]
Copyright © 2025 | WordPress Theme by MH Themes